Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acer Therapeutics Inc (ACER)

Acer Therapeutics Inc (ACER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,736
  • Shares Outstanding, K 11,913
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,420 K
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.44
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.51
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.15 +18.14%
on 09/11/20
2.95 -13.90%
on 08/25/20
-0.18 (-6.62%)
since 08/21/20
3-Month
2.15 +18.14%
on 09/11/20
5.84 -56.51%
on 08/07/20
-0.80 (-23.95%)
since 06/22/20
52-Week
1.08 +135.19%
on 03/23/20
7.25 -64.97%
on 02/20/20
-1.08 (-29.83%)
since 09/20/19

Most Recent Stories

More News
New Strong Sell Stocks for September 3rd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

DENN : 10.18 (+4.62%)
TRN : 19.75 (+3.78%)
ZSAN : 1.7800 (+0.56%)
EQC : 29.76 (+0.64%)
ACER : 2.54 (-1.55%)
LD Micro - 360 Companies Set to Present this Week

LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACRX : 1.8000 (-0.55%)
ACER : 2.54 (-1.55%)
ACU : 22.65 (+1.57%)
AT.VN : 1.610 (-0.62%)
AEY : 2.00 (-1.48%)
ADIL : 1.2700 (-0.78%)
ADTX : 2.0900 (+5.03%)
ADXS : 0.4213 (+1.25%)
AEHR : 1.5050 (-0.33%)
AIM : 2.44 (+19.61%)
AIRI : 1.0939 (+3.20%)
ALIM : 5.16 (-6.86%)
ALJJ : 0.7900 (unch)
ALLT : 9.27 (-2.52%)
ARCT : 41.21 (+1.25%)
AREC : 1.4950 (-2.92%)
AMS : 1.7500 (-0.57%)
ANVS : 4.92 (-0.81%)
APEN : 1.3900 (-0.71%)
APM : 1.6300 (unch)
AQMS : 0.9351 (-1.84%)
AQB : 4.64 (-4.33%)
ARTL : 0.8200 (-4.65%)
ARHH : 0.7900 (-7.06%)
ATOM : 10.04 (-2.62%)
ATOS : 2.37 (-2.07%)
AUTO : 3.38 (+7.99%)
AYRO : 2.82 (-1.05%)
AZRX : 0.7490 (-1.47%)
BELFA : 10.50 (-3.67%)
BCDA : 2.52 (-3.45%)
BIOC : 4.55 (-2.57%)
BHTG : 1.2500 (-2.34%)
BIOL : 0.2859 (-1.41%)
BKEP : 1.4300 (-1.38%)
ATDS : 0.0099 (-1.00%)
ASUR : 7.12 (+0.85%)
BEER.VN : 0.065 (+18.18%)
ANY : 2.51 (+0.80%)
Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant...

ACER : 2.54 (-1.55%)
Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders

ACER : 2.54 (-1.55%)
LD Micro Announces Preliminary List of Presenters for the LD 500

LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACER : 2.54 (-1.55%)
ACU : 22.65 (+1.57%)
AEY : 2.00 (-1.48%)
ADIL : 1.2700 (-0.78%)
ADXS : 0.4213 (+1.25%)
AEHR : 1.5050 (-0.33%)
AIM : 2.44 (+19.61%)
AIRI : 1.0939 (+3.20%)
KERN : 3.98 (-1.97%)
ALIM : 5.16 (-6.86%)
ALLT : 9.27 (-2.52%)
AMS : 1.7500 (-0.57%)
ANVS : 4.92 (-0.81%)
APEN : 1.3900 (-0.71%)
APM : 1.6300 (unch)
AQB : 4.64 (-4.33%)
ARTL : 0.8200 (-4.65%)
ARHH : 0.7900 (-7.06%)
ATOM : 10.04 (-2.62%)
ATOS : 2.37 (-2.07%)
ACU.VN : 0.150 (+3.45%)
AUTO : 3.38 (+7.99%)
AYRO : 2.82 (-1.05%)
AYTU : 1.2750 (-1.92%)
AZRX : 0.7490 (-1.47%)
BLDP : 16.11 (-1.35%)
BELFA : 10.50 (-3.67%)
BCDA : 2.52 (-3.45%)
BIOC : 4.55 (-2.57%)
BMRA : 6.99 (-2.78%)
BSGM : 5.57 (-31.57%)
BLNK : 9.72 (+22.26%)
BKEP : 1.4300 (-1.38%)
CLBS : 1.8500 (+1.09%)
CLXT : 5.96 (+1.36%)
ASUR : 7.12 (+0.85%)
BLGO : 0.1450 (-1.89%)
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc. Investors (ACER)

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. ("Acer" or the "Company") (NASDAQ: ACER) concerning whether the board breached...

ACER : 2.54 (-1.55%)
Acer Therapeutics Discusses Developing COVID-19 Clinical Program, Next Steps with the FDA and Vision for 2020 in New Video Interview on SNN Network

LOS ANGELES, CA / ACCESSWIRE / May 21, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with Chris Schelling, CEO and Founder of Acer Therapeutics...

ACER : 2.54 (-1.55%)
Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant...

ACER : 2.54 (-1.55%)
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health

Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance

ACER : 2.54 (-1.55%)
Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant...

LPBC : 6.3100 (+0.48%)
ACER : 2.54 (-1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACER with:

Business Summary

Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics,...

See More

Key Turning Points

2nd Resistance Point 2.69
1st Resistance Point 2.63
Last Price 2.54
1st Support Level 2.49
2nd Support Level 2.41

See More

52-Week High 7.25
Fibonacci 61.8% 4.89
Fibonacci 50% 4.16
Fibonacci 38.2% 3.44
Last Price 2.54
52-Week Low 1.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar